CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Capricor Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Capricor Therapeutics Inc
8840 Wilshire Blvd, 2nd Floor
Phone: (310) 358-3200p:310 358-3200 BEVERLY HILLS, CA  90211  United States Ticker: CAPRCAPR

Business Summary
Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy. CAP-1002 is advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002 demonstrates immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. The Company leverages its exosome technology, using its StealthX platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins and small molecule therapeutics to potentially treat and prevent a diverse array of diseases.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/202312/31/2023YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Executive Chairman of the Board Frank I.Litvack 67 1/1/2016 9/24/2009
President, Chief Executive Officer, Director LindaMarban 59 1/1/2014 11/21/2013
Chief Financial Officer AnthonyBergmann 37 1/1/2018 11/22/2013
6 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Capricor, Inc. 8700 Beverly Boulevard Los Angeles CA United States

Business Names
Business Name
CAPR
Capricor Therapeutics, Inc.
Capricor, Inc.
5 additional Business Names available in full report.

General Information
Number of Employees: 101 (As of 12/31/2023)
Outstanding Shares: 31,399,667 (As of 3/7/2024)
Shareholders: 126
Stock Exchange: NASD
Federal Tax Id: 880363465
Fax Number: (302) 655-5049


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, March 29, 2024